Allarity Therapeutics, Inc. has completed an amendment to its Preliminary Proxy Statement on Schedule 14A, which was initially filed on February 23, 2024. The United States Securities and Exchange Commission (SEC), through the Division of Corporation Finance Office of Life Sciences, has concluded its review of the amended filing. In a letter dated February 27, 2024, addressed to Thomas Jensen, CEO of Allarity Therapeutics, the SEC issued a reminder to the company and its management regarding their responsibility for the accuracy and adequacy of their disclosures. This communication confirms that the SEC has no further comments on the amendment at this time.

Allarity Therapeutics, Inc. has completed an amendment to its Preliminary Proxy Statement on Schedule 14A, which was initially filed on February 23, 2024. The United States Securities and Exchange Commission (SEC), through the Division of Corporation Finance Office of Life Sciences, has concluded its review of the amended filing. In a letter dated February 27, 2024, addressed to Thomas Jensen, CEO of Allarity Therapeutics, the SEC issued a reminder to the company and its management regarding their responsibility for the accuracy and adequacy of their disclosures. This communication confirms that the SEC has no further comments on the amendment at this time.